Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2007

GE Healthcare Picks Up Wave Biotech, LLC

  • GE Healthcare is acquiring Wave Biotech, LLC, including its subsidiary Wave Europe Pvt. Ltd. GE says the deal will allow the firm to expand its offering of products and services for the manufacture of biopharmaceuticals, such as antibodies and vaccines.

    “The combination of GE Healthcare and Wave Biotech will allow us to expand into new applications and to create a broad offering of added value tools and services for biopharmaceutical manufacture,” says Ann O’Hara, general manager of GE Healthcare’s bioprocess business.

    Wave Biotech develops and manufactures disposable bioreactors. Advantages often cited include rapid installation and lower costs due to eliminating the need for cleaning and validating between batches. The company reports that its single-use bioreactors are also increasingly enabling the manufacture of patient-specific cell and gene therapy products.

    “Our customers will benefit greatly from the global presence and the R&D resources that GE Healthcare brings to the table,” comments Vijay Singh, president and founder of Wave Biotech. “The integration of single-use cell culture with GE Healthcare’s existing filtration and downstream operations will provide a host of new disposable solutions to this growing industry.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »